BioCentury | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

Jason Meyenburg has left Orchard Therapeutics plc (NASDAQ:ORTX) as CCO to become CEO of ophthalmic disease company Gemini Therapeutics Inc. (Cambridge, Mass.). Orchard President and CEO Mark Rothera will assume global commercial leadership responsibilities in...
BioCentury | Jan 19, 2018
Financial News

HalioDx raises first tranche of €18.5M series B

Diagnostic company HalioDx S.A.S. (Marseille, France) raised €9.25 million ($11.3 million) on Jan. 17 in the first tranche of a €18.5 million ($22.6 million) series B round led by new investor PSIM. Other new investors...
BioCentury | Jan 17, 2018
Financial News

HalioDx raises first tranche of €18.5M series B

Diagnostic company HalioDx S.A.S. (Marseille, France) raised €9.25 million ($11.3 million) in the first tranche of a €18.5 million ($22.6 million) series B round led by new investor PSIM. Other new investors Quest for Growth...
BioCentury | Jan 13, 2017
Clinical News

Immunoscore Colon regulatory update

HalioDx launched its Immunoscore Colon diagnostic assay in Europe as an aid to assess prognosis of primary colon cancer. The product, which has CE Mark approval, is an in vitro diagnostic that measures the densities...
BioCentury | Nov 17, 2016
Company News

HalioDx sales and marketing update

HalioDx launched the Immunoseek CR (CD8/PD-L1) to measure expression of PD-L1 on tumor and immune cells and the density of CD8+ T cells. The company said the multiplexed assay, which uses formalin-fixed, paraffin-embedded (FFPE) samples,...
BioCentury | Apr 25, 2016
Company News

NanoString, HalioDx deal

NanoString and HalioDx partnered to develop and commercialize cancer gene expression assays for assessing responses to immunotherapies using NanoString’s nCounter Analysis System. The companies declined to disclose financial details. NanoString Technologies Inc. (NASDAQ:NSTG), Seattle, Wash....
BioCentury | Mar 30, 2015
Financial News

HalioDx completes venture financing

HalioDx , Marseille, France Business: Diagnostic Date completed: 2015-03-23 Type: Venture financing Raised: EUR7.5 million ($8.1 million) Investors: Sham; Sofipaca; MICare; company founders WIR Staff Diagnostic...
BioCentury | Mar 9, 2015
Company News

Qiagen deal

Qiagen’s Qiagen Marseille subsidiary proposed to spin out its leukemia diagnostic manufacturing capacity and other R&D into a standalone company named HalioDx . HalioDx will be granted a non-exclusive license to Qiagen’s pyrosequencing technology. The subsidiary’s...
Items per page:
1 - 8 of 8
BioCentury | Sep 13, 2019
Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

Jason Meyenburg has left Orchard Therapeutics plc (NASDAQ:ORTX) as CCO to become CEO of ophthalmic disease company Gemini Therapeutics Inc. (Cambridge, Mass.). Orchard President and CEO Mark Rothera will assume global commercial leadership responsibilities in...
BioCentury | Jan 19, 2018
Financial News

HalioDx raises first tranche of €18.5M series B

Diagnostic company HalioDx S.A.S. (Marseille, France) raised €9.25 million ($11.3 million) on Jan. 17 in the first tranche of a €18.5 million ($22.6 million) series B round led by new investor PSIM. Other new investors...
BioCentury | Jan 17, 2018
Financial News

HalioDx raises first tranche of €18.5M series B

Diagnostic company HalioDx S.A.S. (Marseille, France) raised €9.25 million ($11.3 million) in the first tranche of a €18.5 million ($22.6 million) series B round led by new investor PSIM. Other new investors Quest for Growth...
BioCentury | Jan 13, 2017
Clinical News

Immunoscore Colon regulatory update

HalioDx launched its Immunoscore Colon diagnostic assay in Europe as an aid to assess prognosis of primary colon cancer. The product, which has CE Mark approval, is an in vitro diagnostic that measures the densities...
BioCentury | Nov 17, 2016
Company News

HalioDx sales and marketing update

HalioDx launched the Immunoseek CR (CD8/PD-L1) to measure expression of PD-L1 on tumor and immune cells and the density of CD8+ T cells. The company said the multiplexed assay, which uses formalin-fixed, paraffin-embedded (FFPE) samples,...
BioCentury | Apr 25, 2016
Company News

NanoString, HalioDx deal

NanoString and HalioDx partnered to develop and commercialize cancer gene expression assays for assessing responses to immunotherapies using NanoString’s nCounter Analysis System. The companies declined to disclose financial details. NanoString Technologies Inc. (NASDAQ:NSTG), Seattle, Wash....
BioCentury | Mar 30, 2015
Financial News

HalioDx completes venture financing

HalioDx , Marseille, France Business: Diagnostic Date completed: 2015-03-23 Type: Venture financing Raised: EUR7.5 million ($8.1 million) Investors: Sham; Sofipaca; MICare; company founders WIR Staff Diagnostic...
BioCentury | Mar 9, 2015
Company News

Qiagen deal

Qiagen’s Qiagen Marseille subsidiary proposed to spin out its leukemia diagnostic manufacturing capacity and other R&D into a standalone company named HalioDx . HalioDx will be granted a non-exclusive license to Qiagen’s pyrosequencing technology. The subsidiary’s...
Items per page:
1 - 8 of 8